Erbitux medicine 100mg/20ml Cetuximab treats certain types of cancer. You need to know how much Cetuximab costs? You do not know where Erbitux is sold? index-china is an address specializing in trading Erbitux medicine in Ho Chi Minh City, Hanoi, Da Nang, Can Tho … and nationwide.
Erbitux medicine 100mg/20ml Cetuximab treatment of some epidermal growth cancers
- Trade name: Erbitux
- Active ingredient: Cetuximab
- Content: 100mg/20ml
- Form: Infusion solution
- Package: 100mg/20ml 1 box
- Erbitux Drug Prices: COMMENT below for prices OR Click on the link: https://thuoclp.com/chatFB type “Erbitux”
What is Erbitux?
- Erbitux is used to treat certain cancers whose protein on their cell surface is called EGFR (epidermal growth factor receptor).
- When a growth factor called EGF attaches to EGFR, it will turn on signals in the cell that make it grow and divide to form more cells.
- In many human tumors, there are excessive activation of these receptors, leading to increased uncontrolled growth of cancer cells and development into a tumor.
Indications for treatment of Erbitux drugs
Head and neck cancer
Erbitux (cetuximab) is approved:
- In combination with radiation therapy for the initial treatment of a locally or regionally progressive head and neck cancer
- Combined with platinum-based chemotherapy and fluorouracil to provide initial treatment for patients with a certain type of head and neck cancer, where the tumor has returned in the same place or spread to other parts of the the body
- Only used to treat patients with a certain head and neck cancer whose tumor has returned in the same place or spread to other parts of the body and the disease has progressed after chemotherapy based on platinum
Metastatic colorectal cancer
Erbitux is approved to treat some patients with colorectal cancer that has spread to other parts of the body. Only patients whose tumors are wild type KRAS (that is, they have a negative gene mutated KRAS) and tumors with a protein called epidermal growth factor receptor (EGFR) can use Erbitux. Treatment with Erbitux is given in three ways:
- Combined with FOLFIRI (irinotecan, fluorouracil, leucovorin) for patients receiving this cancer for the first time
- In combination with another chemotherapy drug, irinotecan, for patients who have advanced disease after receiving chemotherapy with irinotecan
- As a sole agent:
- For patients with advanced disease after taking both irinotecan and oxaliplatin
- For patients who cannot tolerate chemotherapy with irinotecan
Erbitux is not approved to treat colorectal cancer in patients with a tumor with a gene mutation called RAS (commonly referred to as a “RAS mutation”) or in patients who do not know the mutation status genes.
How Erbitux works
- The active substance in Erbitux is cetuximab. It belongs to a class of drugs called monoclonal antibodies. Monoclonal antibodies are special proteins that recognize and attach to other unique proteins.
- Erbitux attaches to EGFR more closely than EGF and thus hinders the growth of cancer cells.
- Erbitux is contraindicated in patients with known severe hypersensitivity reactions (grade 3 or 4) with cetuximab.
- The combination of Erbitux with oxaliplatin-containing chemotherapy is contraindicated for patients with mutated RAS colorectal cancer (mCRC) or unknown RAS mCRC status.
- Before starting combination therapy, consideration should be given to the contraindication to the use of chemotherapy or radiotherapy agents.
Dosage and usage of Erbitux
Recommended dosage for squamous cell carcinoma of the head and neck (SCCHN)
Combined with radiation therapy or therapy based on platinum and fluorouracil
- The recommended starting dose is 400 mg / m 2 administered one week before the start of radiation therapy or on the first day of platinum and fluorouracil treatment in the form of a 120 minute intravenous infusion.
- The next recommended dose (all other infusions) is 250 mg / m2 every week as a 60 minute infusion during radiotherapy (6 weeks7) or until disease progression or unacceptable toxicity. when used in combination with platinum-based therapy and fluorouracil.
- Complete administration of Erbitux 1 hour before radiation therapy or platinum treatment with fluorouracil.
- The recommended initial dose is 400 mg / m 2 administered as a 120 minute intravenous infusion.
- The next recommended dose (all other infusions) is 250 mg / m2 every week as a 60-minute infusion until the disease progresses or the intolerance is toxic.
Recommended dosage for colorectal cancer (CRC)
Determine the status of EGFR expression with FDA-approved tests before starting treatment. Confirm no Ras mutations before starting treatment with Erbitux. Information about FDA-approved tests for detecting K-Ras mutations in patients with metastatic CRC is available at:
- The recommended initial dose, as monotherapy or in combination with irinotecan or FOLFIRI (irinotecan, fluorouracil, leucovorin), is 400 mg / m 2 administered as a 120 minute intravenous infusion.
- The next recommended dose, either as a monotherapy or in combination with irinotecan or FOLFIRI, is 250 mg / m 2 per week as a 60-minute infusion until the disease progresses or the toxicity is unacceptable.
- Complete administration of Erbitux 1 hour before irinotecan or FOLFIRI.
- Book with histamine-1 (H 1) receptor antagonists intravenously 30 minutes 60 minutes before the first dose or the next dose as needed
Side effects of Erbitux
Some side effects may occur during the infusion. Tell your caregiver right away if you feel short of breath, weak or dizzy, nauseous, itchy or wheezing, making noisy breathing, or a hoarse voice during the infusion. See your doctor right away if you have the following symptoms:
- slow heartbeat, weak pulse, fainting, slow breathing (breathing may stop);
- Sudden chest pain, wheezing, feeling short of breath;
- dry cough, or coughing up blood;
- fever, sore mouth, sore throat;
- skin rashes that resemble acne or any serious skin rash;
- redness or crust around your hair follicles;
- redness, warmth, or puffiness under your skin;
- eye pain or redness, eyelids, purulent or crusting in the eye, vision problems or increased photosensitivity;
- kidney problems – minor or no urination, swelling in your legs or ankles; or
- Signs of electrolyte imbalance increased thirst or urination, confusion, vomiting, constipation, muscle aches or weakness, leg cramps, bone pain, lack of energy, arrhythmia, tingly feeling.
Common side effects may include:
- mild itching or rash;
- change your nails or toenails;
- dry, cracked, or swollen skin;
- diarrhea; or
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
Warning before taking Erbitux
Before you start treatment with Erbitux, tell your doctor:
- If you have any history of heart disease or heart disease.
- If you have a history of breathing problems or other lung problems.
- If you are pregnant or if you plan to become pregnant. Because Erbitux can be harmful to an unborn baby, you should use contraception and not get pregnant during treatment with Erbitux and for at least 2 months after your last Erbitux dose. If you become pregnant during treatment or within 2 months after the last dose, talk to your doctor.
- If you are breastfeeding. Erbitux can be transmitted through breast milk. Due to the potential for serious side effects in infants breastfed from Erbitux, you should not breastfeed during Erbitux therapy and for 2 months after the last Erbitux dose.
- Tell your doctor about all medications you are taking, including prescription and over-the-counter medicines.
Other drug interactions with Erbitux
- In combination with platinum-based chemotherapy, the frequency of severe neutropenia or agranulocytosis may increase, and may therefore lead to higher rates of infectious complications such as fever-induced neutropenia, pneumonia and sepsis compared to platinum chemotherapy alone.
- In combination with fluoropyrimidine, the incidence of myocardial ischemia including myocardial infarction and congestive heart failure as well as the frequency of limb syndrome (erythrodysaesthesia) have increased compared to fluoropyrimidine.
- In combination with capecitabine and oxaliplatin (XELOX), the frequency of severe diarrhea may be increased.
- An official interaction study showed that the pharmacokinetic properties of cetuximab remained unchanged after the same dose of irinotecan. Similarly, the pharmacokinetics of irinotecan does not change when concomitant use of cetuximab.
- No formal interaction studies with cetuximab have been done in humans.
Preservation of Erbitux medicine
- Erbitux must be kept in a refrigerator at 2 ° C to 8 ° C, but it must not be frozen.
- Keep out of reach of children and pets
- Each vial is for one use only. Once the required amount of solution has been removed from the vial, all remaining solutions must be discarded.
How much does Erbitux 100mg/20ml Cetuximab cost?
- How much does Cetuximab Erbitux 100mg/20ml cost? Please COMMENT below or Contact index-china 0933049874 (Zalo / Facebook / Viber / Whatsapp) buying and selling brand name drugs in Ho Chi Minh City, Hanoi, Da Nang City, Can Tho City, … nationwide
Where is Erbitux 100mg/20ml medicine Cetuximab bought and sold?
- Where to know where to buy and sell Erbitux 100mg/20ml Cetuximab? Please COMMENT below or Contact index-china 0933049874 (Zalo / Facebook / Viber / Whatsapp) buying and selling brand name drugs in Ho Chi Minh City, Hanoi, Da Nang City, Can Tho City, … nationwide
Assoc.Prof.Dr. Tran Ngoc Anh is currently Hanoi Medical University Hospital, Associate Professor, Department of Internal Medicine, Gastroenterology and Head of Department of General-Uematology of Hanoi Medical University. Consulting doctor at ThuocLP Pharmacy.
Professional qualifications, Academic degrees – Education:
Graduated from General Practitioner System, Hanoi Medical University
Graduated with a Master degree in Internal Medicine, Hanoi Medical University
Graduated from the training program specialized in Gastrointestinal, Henri Mondor Institute Center, University of Paris 6, French Republic 1996-1997; 1999
Graduated from the training program specialized in Gastrointestinal, North Royal Sydney Hospital, Australia; 2002
Graduated from a training program specialized in chronic liver diseases, Pizza, Italy 2009
Graduated with a PhD in Gastrointestinal, Hanoi Medical University
Associate Professor, Gastroenterology, Hanoi Medical University
Training and Scientific Research:
Published more than 200 articles in domestic and international specialized journals
Editor of many monographs and participates in compiling 2 textbooks.
Guide many students and graduate students of Hanoi Medical University
Manager of many grassroots research projects
Certificate of Good Clinical Practice (GCP: 2012, 2015), Ministry of Health
Specialized certificates: General gastrointestinal endoscopy, Interventional gastrointestinal endoscopy, General gastrointestinal ultrasound, Interventional gastrointestinal ultrasound (Bach Mai BV), Chronic liver disease.